低分子肝素钙预防ICU患者静脉血栓栓塞症的临床观察
x

请在关注微信后,向客服人员索取文件

篇名: 低分子肝素钙预防ICU患者静脉血栓栓塞症的临床观察
TITLE:
摘要: 目的:观察低分子肝素钙预防ICU患者静脉血栓栓塞症(VTE)的疗效及安全性。方法:将572例VTE风险评估为高危的患者按随机数字表法分为试验组和对照组,各286例。试验组患者给予低分子肝素钙注射液0.3~0.6 ml,im,qd;对照组患者给予利伐沙班片10 mg,po,qd。比较两组患者VTE发生率、血小板计数、凝血功能、生存质量评分和不良反应发生情况。结果:试验组患者VTE发生率(0.3%)明显低于对照组(2.1%),差异有统计学意义(P<0.05);两组患者治疗前后血小板计数、凝血酶原时间、活化部分凝血酶原时间和纤维蛋白原等指标比较,差异均无统计学意义(P>0.05);试验组患者躯体健康、躯体角色功能、总体健康、情绪角色功能和心理健康等项目较对照组改善更明显,差异均有统计学意义(P>0.05)。两组患者均未见明显不良反应发生。结论:低分子肝素钙预防VTE效果明显,且在改善患者生存质量的同时,不会影响其血小板计数及凝血功能,具有良好的安全性。
ABSTRACT: OBJECTIVE: To observe the safety and therapeutic efficacy of low molecular weight heparin calcium in the prevention of venous thromboembolism (VTE) of ICU patients. METHODS: 572 VTE patients were randomly divided into trial group and control group, with 286 cases in each group. Trial group was given Low molecular weight heparin calcium injection 0.3-0.6 ml,im,qd; control group was given Rivaroxaban tablet 10 mg, po, qd. The incidence of VTE, platelet count, coagulation function, quality score of life and the occurrence of ADR were compared between 2 groups. RESULTS: The incidence of VTE in trial group (0.3%) was significantly lower than control group (2.1%), with statistical significance (P<0.05). There was no statistical significance in platelet count, prothrombin time, APPT,  fibrinogen and other indexes between 2 groups before and after treatment (P>0.05). The physical health, body function and role, general health, emotional role function, mental health and other aspects of trial group were improved significantly, compared to control group, with statistical significance (P>0.05). No obvious ADR was found in 2 groups. CONCLUSIONS: Low molecular weight heparin calcium can effectively prevent VTE and improve the quality of life, while doesn’t influence platelet count and coagulation function with good safety.
期刊: 2016年第27卷第20期
作者: 傅振会,任波,赵群都
AUTHORS: FU Zhenhui,REN Bo,ZHAO Qundu
关键字: 低分子肝素钙;重症监护室;静脉血栓栓塞症;安全性;有效性
KEYWORDS: Low molecular weight heparin calcium; ICU; Venous thromboembolism; Safety; Efficacy
阅读数: 258 次
本月下载数: 5 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!